Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

← catalyst calendar

NCT03706690 · results posted

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
407actual
Sites
87
Countries
China, Hong Kong, India +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2018-11-27actualWhen the study began enrolling
Primary completion2024-06-23actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-02-26estimatedThe whole study's end, after follow-up
First posted2018-10-16actualWhen this record first appeared on the registry
Results posted2025-02-12actualWhen the sponsor posted results to the registry
Record updated2026-08-06actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • Drug: Durvalumab — also filed as MEDI4736
  • Other: Placebo

Primary outcome

what the primary-completion date above is the date OF
Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)
measured Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2023-08-28 · 5.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-03-18 · 1.6 MB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed